Freenome, Inc. FRNM
10.41 USD -0.20 (-1.89%)
Regular-session close
10.41 0.00 0.00%
After hours · Nov 13, 4:01 PM ET
9.95 Day range 10.70
9.99 52-week range 17.11
- YTD
- -20.11%
- 1 year
- -3.52%
News
defenseworld.net Freenome (NASDAQ:FRNM) Stock Has Average Target Price of $18.00 According to Analysts Shares of Freenome (NASDAQ: FRNM - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One…
marketbeat.com Freenome Q3 Earnings Call Highlights Freenome NASDAQ: FRNM reported third-quarter revenue of $183.5 million, driven largely by revenue recognition following the U.S. Food and Drug Administration's approval of its blood-based colorectal…
benzinga.com Freenome Q3 2026 Earnings Call Transcript Freenome (NASDAQ:FRNM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com UPDATE: Freenome Q3 Adj. EPS $1.10 Beats $0.41 Estimate, Sales $183.489M Beat $105.866M Estimate Freenome (NASDAQ:FRNM) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.41 by 168.29 percent. This is a 222.22 percent increase over losses of $(0.90)…
globenewswire.com Freenome Reports Third Quarter 2026 Financial Results – Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –
benzinga.com Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests – Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday U.S. stocks mixed, Nasdaq falls 0.1%. Gap Inc shares rise 15.2% on strong earnings and raised guidance. Other big gainers include Elastic NV, Solstice Advanced Materials Inc, and Pagerduty Inc.- benzinga.com Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21 Guggenheim analyst Subbu Nambi initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $21.
benzinga.com Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock https://www.sec.gov/ix?doc=/Archives/edgar/data/0002017526/000114036126033585/ny20080283x1_s1.htm
benzinga.com TD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17 TD Cowen analyst Dan Brennan initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.- benzinga.com Jefferies Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17 Jefferies analyst Tycho Peterson initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.
benzinga.com BTIG Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17 BTIG analyst Mark Massaro initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.- benzinga.com Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18 Leerink Partners analyst Puneet Souda initiates coverage on Freenome (NASDAQ:FRNM) with a Outperform rating and announces Price Target of $18.
benzinga.com Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen Lung The designation applies to the proposed use of SimpleScreen Lung in adults ages 50 to 80 who have at least a 20 pack-year smoking history and are not currently participating in guideline-recommended…
benzinga.com Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment Screening is for colorectal cancer (CRC) in adults 45 and older who are at average risk for the disease. Abbott will exclusively commercialize the test in the U.S. this fall, expanding its CRC…